What is MRD?
Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.
LEARN MORE ABOUT MRD
clonoSEQ for Patients
With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.
LEARN MORE ABOUT MRDclonoSEQ for Clinicians
clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.
How clonoSEQ worksNews and Updates
clonoSEQ Assay Medicare Coverage Expanded to Include MRD in CLL
clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.
May, 2020
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.
View Press ReleaseApril, 2020
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.
View Press ReleaseWhat We’re Sharing
Follow UsTim is a #myeloma patient with a powerful story to share. Watch his story and learn about MRD testing. clonoSEQ is FDA-cleared to assess MRD in B-ALL & MM in patients' bone marrow. For important info. incl. test limitations: https://t.co/sE39cuHWh3 #mmsm #myelomaawarenessmonth pic.twitter.com/oBlKaFT3Ew
— clonoSEQ (@clonoSEQ) March 31, 2020
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Contact Us
Make an inquiry to learn more about our products.